½ÃÀ庸°í¼­
»óǰÄÚµå
1596745

½ºÅÙÆ® ±×·¡ÇÁÆ® ½ÃÀå : Á¦Ç°, À¯Çü, ¿ëµµº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Stent Grafts Market by Product (Endovascular Stent Graft System, Synthetic Stent Graft System), Type (Aorta-Uni-Iliac, Bifurcated Stent Grafts), Application - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 194 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

½ºÅÙÆ® ±×·¡ÇÁÆ® ½ÃÀåÀº 2023³â¿¡ 52¾ï 1,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 57¾ï 2,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 9.85%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 100¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

½ºÅÙÆ® ±×·¡ÇÁÆ® ½ÃÀåÀº ÁÖ·Î µ¿¸Æ·ù ¹× ±âŸ Ç÷°ü ÁúȯÀ» Ä¡·áÇϱâ À§ÇÑ Ç÷°ü ³» Ä¡·á¿¡ Àû¿ëÇÏ´Â °ÍÀ¸·Î Á¤Àǵ˴ϴÙ. ½ºÅÙÆ® ±×·¡ÇÁÆ®´Â Á¾Á¾ ´ÙÅ©·ÐÀ̳ª PTFE¿Í °°Àº Àç·á·Î ¸¸µé¾îÁö°í ±Ý¼Ó ÇÁ·¹ÀÓ¿öÅ©¿¡ ÀÇÇØ ÁöÁöµÇ´Â ÇÕ¼º Æ©ºê·Î, ¾àÇØÁø µ¿¸Æº®À» º¸°­Çϱâ À§ÇØ ¼øÈ¯°è¿¡ »ðÀԵǴ ÇÕ¼º Æ©ºêÀÔ´Ï´Ù. ½ºÅÙÆ® ±×·¡ÇÁÆ®ÀÇ Çʿ伺Àº ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡, °í·ÉÈ­ ¹× ÃÖ¼Ò Ä§½À ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. ÁÖ·Î º¹ºÎ ¹× ÈäºÎ ´ëµ¿¸Æ·ù¿¡ ÁÖ·Î »ç¿ëµÇ¸ç, ¸»ÃÊ Ç÷°ü ¼öº¹¿¡ ´ëÇÑ °ü½Éµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÃÖÁ¾ »ç¿ëÀÚ´Â ÁÖ·Î º´¿ø, Àü¹® Ŭ¸®´Ð, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) µîÀÔ´Ï´Ù. ÁÖ¿ä ¼ºÀå ¿äÀÎÀº Àç·á ±â¼úÀÇ ¹ßÀü, ÀÇ·áºñ ÁöÃâ Áõ°¡, ȸº¹ ±â°£ ´ÜÃàÀ¸·Î ÀÎÇÑ ÃÖ¼Ò Ä§½À ¼ö¼ú¿¡ ´ëÇÑ È¯ÀÚ ¼±È£µµ Áõ°¡ µîÀÔ´Ï´Ù. ½ÃÀåÀº ÀÇ·á ÀÎÇÁ¶ó È®´ë¿Í Ç÷°ü ÀÇ·á ±â¼ú ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡·Î ½ÅÈï±¹¿¡¼­ »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÒ Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÌ ½ÃÀåÀº ³ôÀº Àåºñ ºñ¿ë, ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç, ¼÷·ÃµÈ Àü¹®°¡°¡ ÇÊ¿äÇÑ Ã·´Ü ¼ö¼úÀÇ Æ¯¼ºÀ¸·Î ÀÎÇØ Á¢±Ù¼ºÀ» ÀúÇØÇÒ ¼ö ÀÖ´Â ÇѰ迡 Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÀÇ·á ½Ã½ºÅÛ¿¡¼­ ºñ¿ë ¾ïÁ¦¿Í ¿£µå¸®Å©¿Í °°Àº ÀáÀçÀû ÇÕº´ÁõÀº ÇöÀç ÁøÇà ÁßÀÎ °úÁ¦ÀÔ´Ï´Ù. Çõ½ÅÀÇ ±âȸ´Â ºñ¿ë È¿À²ÀûÀÎ »ýºÐÇØ¼º ÀÌ½ÄÆíÀÇ °³¹ß, ±âÁ¸ Àç·áÀÇ À¯¿¬¼º ¹× ³»±¸¼º Çâ»ó, ÀΰøÁö´ÉÀ» Ȱ¿ëÇÑ ¼ö¼ú °á°ú °³¼± ¹× ȯÀÚ ¸ð´ÏÅ͸µ¿¡ ÀÖ½À´Ï´Ù. ȯÀÚ °³°³ÀÎÀÇ ÇüÅ¿¡ ¸Â´Â ¸ÂÃãÇü ½ºÅÙÆ® ÀÌ½ÄÆí°ú ´õ ÀÛ°í º¹ÀâÇÑ Ç÷°ü º´º¯À» Ä¡·áÇϱâ À§ÇÑ ½ºÅÙÆ® Àû¿ë È®´ë¿¡ ÁýÁßÇÏ´Â °ÍÀÌ »ç¾÷ ¼ºÀåÀÇ ¼±ºÀ¿¡ ¼³ ¼ö ÀÖ½À´Ï´Ù. ±â¼ú ¹ßÀü°ú ÀÇ·á ¼ö¿äÀÇ º¯È­¿¡ µû¶ó ½ÃÀåÀÇ Æ¯¼ºÀÌ ¿ªµ¿ÀûÀ¸·Î º¯È­Çϰí Àֱ⠶§¹®¿¡ Àü·«Àû ¿¬±¸¿Í »õ·Î¿î ¼Ö·ç¼ÇÀÇ ¹ÎøÇÑ ÀûÀÀ¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¼ö¿ä°¡ ÀÖÀ¸¸ç, À̸¦ ÅëÇØ °æÀï¿¡¼­ ¿ìÀ§¸¦ Á¡ÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 52¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 57¾ï 2,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 100¾ï 7,000¸¸ ´Þ·¯
CAGR(%) 9.85%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ½ºÅÙÆ® ±×·¡ÇÁÆ® ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®À» °ø°³ÇÕ´Ï´Ù.

½ºÅÙÆ® ÀÌ½Ä ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«Àû ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ½ÉÀ庴, ºñ¸¸, ´ç´¢º´ ȯÀÚ Áõ°¡
    • Àúħ½À ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä
    • ³ë³âÃþ¿¡¼­ ´ëµ¿¸Æ·ù À¯º´·ü Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ½ºÅÙÆ® À̽ļú Ä¡·á¿¡ µû¸¥ À§Ç輺
  • ½ÃÀå ±âȸ
    • »õ·Î¿î Ç÷°ü ³» ½ºÅÙÆ® ÀÌ½Ä ½Ã½ºÅÛ °³¹ß
    • ±â¼ú ¹ßÀü°ú ÀÓ»ó °Ë»ç Áõ°¡
    • Ææ½ºÇü ½ºÅÙÆ® ÀÌ½Ä ±â¼ú ¹ßÀü
  • ½ÃÀå °úÁ¦
    • ÀÎÁöµµ ºÎÁ·°ú Ä¡·áºñ Æøµî

Porter's Five Forces: ½ºÅÙÆ® ±×·¡ÇÁÆ® ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â µ¥ Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. PorterÀÇ Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀïÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ¸ð»öÇϱâ À§ÇÑ ¸íÈ®ÇÑ ¹æ¹ýÀ» ¼³¸íÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇÏ°í ¾àÁ¡À» º¸¿ÏÇϸç ÀáÀçÀû µµÀüÀ» ÇÇÇÔÀ¸·Î½á º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ½ºÅÙÆ® ±×·¡ÇÁÆ® ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ½ºÅÙÆ® ±×·¡ÇÁÆ® ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ ´ã°í ÀÖÀ¸¸ç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀ̰í Àû±ØÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ½ºÅÙÆ® ÀÌ½Ä ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

½ºÅÙÆ® ÀÌ½Ä ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ º¥´õÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ¼¼ºÐÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÏ¿© °ø±Þ¾÷ü°¡ Ä¡¿­ÇÑ °æÀï¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º: ½ºÅÙÆ® ±×·¡ÇÁÆ® ½ÃÀå¿¡¼­ÀÇ º¥´õÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ½ºÅÙÆ® ±×·¡ÇÁÆ® ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ: ½ºÅÙÆ® ÀÌ½Ä ½ÃÀå¿¡¼­ ¼º°øÀÇ ±æÀ» ±×¸³´Ï´Ù.

½ºÅÙÆ® ±×·¡ÇÁÆ® ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÎ¹®¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·ÂÀ» Æò°¡ÇÕ´Ï´Ù.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÎ¹®ÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» ±â¼úÇϰí ÀÖ½À´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, »ê¾÷ÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ, ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

    Á¦6Àå ½ºÅÙÆ® ±×·¡ÇÁÆ® ½ÃÀå : Á¦Ç°º°

    • ¼­·Ð
    • Ç÷°ü³» ½ºÅÙÆ® ±×·¡ÇÁÆ® ½Ã½ºÅÛ
    • ÇÕ¼º ½ºÅÙÆ® ±×·¡ÇÁÆ® ½Ã½ºÅÛ

    Á¦7Àå ½ºÅÙÆ® ±×·¡ÇÁÆ® ½ÃÀå : À¯Çüº°

    • ¼­·Ð
    • Aorta-Uni-Iliac
    • Bifurcated Stent Grafts

    Á¦8Àå ½ºÅÙÆ® ±×·¡ÇÁÆ® ½ÃÀå : ¿ëµµº°

    • ¼­·Ð
    • º¹ºÎ ´ëµ¿¸Æ·ù
    • ÈäºÎ ´ëµ¿¸Æ·ù

    Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ ½ºÅÙÆ® ±×·¡ÇÁÆ® ½ÃÀå

    • ¼­·Ð
    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
    • ¹Ì±¹

    Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ºÅÙÆ® ±×·¡ÇÁÆ® ½ÃÀå

    • ¼­·Ð
    • È£ÁÖ
    • Áß±¹
    • Àεµ
    • Àεµ³×½Ã¾Æ
    • ÀϺ»
    • ¸»·¹À̽þÆ
    • Çʸ®ÇÉ
    • ½Ì°¡Æ÷¸£
    • Çѱ¹
    • ´ë¸¸
    • ű¹
    • º£Æ®³²

    Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ½ºÅÙÆ® ±×·¡ÇÁÆ® ½ÃÀå

    • ¼­·Ð
    • µ§¸¶Å©
    • ÀÌÁýÆ®
    • Çɶõµå
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • À̽º¶ó¿¤
    • ÀÌÅ»¸®¾Æ
    • ³×´ú¶õµå
    • ³ªÀÌÁö¸®¾Æ
    • ³ë¸£¿þÀÌ
    • Æú¶õµå
    • īŸ¸£
    • ·¯½Ã¾Æ
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ½ºÆäÀÎ
    • ½º¿þµ§
    • ½ºÀ§½º
    • ÅÍŰ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • ¿µ±¹

    Á¦12Àå °æÀï ±¸µµ

    • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
    • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023³â
    • °æÀï ½Ã³ª¸®¿À ºÐ¼®
    • Àü·« ºÐ¼®°ú Á¦¾È

    ±â¾÷ ¸®½ºÆ®

    • Abbott Laboratories
    • BioStable Science & Engineering, Inc.
    • Bolton Medical, Inc.
    • Cardiatis SA
    • Cardinal Health, Inc.
    • Cook Group
    • Edwards Lifesciences Corporation
    • ENDOLOGIX, INC.
    • InSitu Technologies Inc.
    • JOTEC GmbH
    • LeMaitre Vascular, Inc.
    • Medtronic Plc
    • MicroPort Scientific Corporation
    • Terumo Aortic
    • W. L. Gore & Associates, Inc.
    LSH

    The Stent Grafts Market was valued at USD 5.21 billion in 2023, expected to reach USD 5.72 billion in 2024, and is projected to grow at a CAGR of 9.85%, to USD 10.07 billion by 2030.

    The stent grafts market is primarily defined by its application in endovascular procedures aimed at treating aneurysms and other vascular conditions. Stent grafts are synthetic tubes, often made from materials like Dacron or PTFE, supported by a metal framework, which are inserted into the circulatory system to reinforce weakened arterial walls. The necessity for stent grafts arises from the increasing prevalence of cardiovascular diseases, aging populations, and the demand for minimally invasive surgical procedures. Applications predominantly focus on abdominal and thoracic aortic aneurysms, with burgeoning interest in peripheral vascular repairs. End-users primarily include hospitals, specialty clinics, and ambulatory surgical centers. Key growth influencers comprise advancements in material technology, rise in healthcare expenditures, and surging patient preference for minimally invasive procedures due to shorter recovery periods. The market is poised to leverage newer opportunities in emerging economies driven by escalating healthcare infrastructure and increased investments towards R&D in vascular health technologies. However, the market faces limitations such as high device costs, stringent regulatory requirements, and the sophisticated nature of surgeries necessitating skilled professionals, which can impede accessibility. Cost-containment in healthcare systems and potential complications such as endoleaks are ongoing challenges. Innovation opportunities lie in developing cost-effective biodegradable grafts, enhancing flexibility and durability of existing materials, and harnessing artificial intelligence for improving procedural outcomes and patient monitoring. A focus on customizing stent grafts for individual patient morphology and expanding stent applications to treat smaller and more complex vascular conditions may spearhead business growth. The nature of the market remains dynamic, driven by both technological advancements and evolving healthcare needs, implying a continuous demand for strategic research and the agile adaptation of novel solutions to stay ahead in the competitive landscape.

    KEY MARKET STATISTICS
    Base Year [2023] USD 5.21 billion
    Estimated Year [2024] USD 5.72 billion
    Forecast Year [2030] USD 10.07 billion
    CAGR (%) 9.85%

    Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Stent Grafts Market

    The Stent Grafts Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

    • Market Drivers
      • Growing number of people suffering from cardiac disorder, obesity, and diabetes
      • Demand for minimally invasive procedures for surgeries
      • Increasing prevalence of aortic aneurysm among the older population
    • Market Restraints
      • Risk involved in the treatment with stent grafts
    • Market Opportunities
      • Development of new endovascular stent-graft system
      • Technological advancements and increasing number of clinical trials
      • Advancements in fenestrated stent graft technology
    • Market Challenges
      • Lack of awareness and high cost of treatment

    Porter's Five Forces: A Strategic Tool for Navigating the Stent Grafts Market

    Porter's five forces framework is a critical tool for understanding the competitive landscape of the Stent Grafts Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

    PESTLE Analysis: Navigating External Influences in the Stent Grafts Market

    External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Stent Grafts Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

    Market Share Analysis: Understanding the Competitive Landscape in the Stent Grafts Market

    A detailed market share analysis in the Stent Grafts Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

    FPNV Positioning Matrix: Evaluating Vendors' Performance in the Stent Grafts Market

    The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Stent Grafts Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

    Strategy Analysis & Recommendation: Charting a Path to Success in the Stent Grafts Market

    A strategic analysis of the Stent Grafts Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

    Key Company Profiles

    The report delves into recent significant developments in the Stent Grafts Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, BioStable Science & Engineering, Inc., Bolton Medical, Inc., Cardiatis SA, Cardinal Health, Inc., Cook Group, Edwards Lifesciences Corporation, ENDOLOGIX, INC., InSitu Technologies Inc., JOTEC GmbH, LeMaitre Vascular, Inc., Medtronic Plc, MicroPort Scientific Corporation, Terumo Aortic, and W. L. Gore & Associates, Inc..

    Market Segmentation & Coverage

    This research report categorizes the Stent Grafts Market to forecast the revenues and analyze trends in each of the following sub-markets:

    • Based on Product, market is studied across Endovascular Stent Graft System and Synthetic Stent Graft System.
    • Based on Type, market is studied across Aorta-Uni-Iliac and Bifurcated Stent Grafts.
    • Based on Application, market is studied across Abdominal Aortic Aneurysm and Thoracic Aortic Aneurysm.
    • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

    The report offers a comprehensive analysis of the market, covering key focus areas:

    1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

    2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

    3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

    4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

    5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

    The report also answers critical questions to aid stakeholders in making informed decisions:

    1. What is the current market size, and what is the forecasted growth?

    2. Which products, segments, and regions offer the best investment opportunities?

    3. What are the key technology trends and regulatory influences shaping the market?

    4. How do leading vendors rank in terms of market share and competitive positioning?

    5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

    Table of Contents

    1. Preface

    • 1.1. Objectives of the Study
    • 1.2. Market Segmentation & Coverage
    • 1.3. Years Considered for the Study
    • 1.4. Currency & Pricing
    • 1.5. Language
    • 1.6. Stakeholders

    2. Research Methodology

    • 2.1. Define: Research Objective
    • 2.2. Determine: Research Design
    • 2.3. Prepare: Research Instrument
    • 2.4. Collect: Data Source
    • 2.5. Analyze: Data Interpretation
    • 2.6. Formulate: Data Verification
    • 2.7. Publish: Research Report
    • 2.8. Repeat: Report Update

    3. Executive Summary

    4. Market Overview

    5. Market Insights

    • 5.1. Market Dynamics
      • 5.1.1. Drivers
        • 5.1.1.1. Growing number of people suffering from cardiac disorder, obesity, and diabetes
        • 5.1.1.2. Demand for minimally invasive procedures for surgeries
        • 5.1.1.3. Increasing prevalence of aortic aneurysm among the older population
      • 5.1.2. Restraints
        • 5.1.2.1. Risk involved in the treatment with stent grafts
      • 5.1.3. Opportunities
        • 5.1.3.1. Development of new endovascular stent-graft system
        • 5.1.3.2. Technological advancements and increasing number of clinical trials
        • 5.1.3.3. Advancements in fenestrated stent graft technology
      • 5.1.4. Challenges
        • 5.1.4.1. Lack of awareness and high cost of treatment
    • 5.2. Market Segmentation Analysis
    • 5.3. Porter's Five Forces Analysis
      • 5.3.1. Threat of New Entrants
      • 5.3.2. Threat of Substitutes
      • 5.3.3. Bargaining Power of Customers
      • 5.3.4. Bargaining Power of Suppliers
      • 5.3.5. Industry Rivalry
    • 5.4. PESTLE Analysis
      • 5.4.1. Political
      • 5.4.2. Economic
      • 5.4.3. Social
      • 5.4.4. Technological
      • 5.4.5. Legal
      • 5.4.6. Environmental

    6. Stent Grafts Market, by Product

    • 6.1. Introduction
    • 6.2. Endovascular Stent Graft System
    • 6.3. Synthetic Stent Graft System

    7. Stent Grafts Market, by Type

    • 7.1. Introduction
    • 7.2. Aorta-Uni-Iliac
    • 7.3. Bifurcated Stent Grafts

    8. Stent Grafts Market, by Application

    • 8.1. Introduction
    • 8.2. Abdominal Aortic Aneurysm
    • 8.3. Thoracic Aortic Aneurysm

    9. Americas Stent Grafts Market

    • 9.1. Introduction
    • 9.2. Argentina
    • 9.3. Brazil
    • 9.4. Canada
    • 9.5. Mexico
    • 9.6. United States

    10. Asia-Pacific Stent Grafts Market

    • 10.1. Introduction
    • 10.2. Australia
    • 10.3. China
    • 10.4. India
    • 10.5. Indonesia
    • 10.6. Japan
    • 10.7. Malaysia
    • 10.8. Philippines
    • 10.9. Singapore
    • 10.10. South Korea
    • 10.11. Taiwan
    • 10.12. Thailand
    • 10.13. Vietnam

    11. Europe, Middle East & Africa Stent Grafts Market

    • 11.1. Introduction
    • 11.2. Denmark
    • 11.3. Egypt
    • 11.4. Finland
    • 11.5. France
    • 11.6. Germany
    • 11.7. Israel
    • 11.8. Italy
    • 11.9. Netherlands
    • 11.10. Nigeria
    • 11.11. Norway
    • 11.12. Poland
    • 11.13. Qatar
    • 11.14. Russia
    • 11.15. Saudi Arabia
    • 11.16. South Africa
    • 11.17. Spain
    • 11.18. Sweden
    • 11.19. Switzerland
    • 11.20. Turkey
    • 11.21. United Arab Emirates
    • 11.22. United Kingdom

    12. Competitive Landscape

    • 12.1. Market Share Analysis, 2023
    • 12.2. FPNV Positioning Matrix, 2023
    • 12.3. Competitive Scenario Analysis
    • 12.4. Strategy Analysis & Recommendation

    Companies Mentioned

    • 1. Abbott Laboratories
    • 2. BioStable Science & Engineering, Inc.
    • 3. Bolton Medical, Inc.
    • 4. Cardiatis SA
    • 5. Cardinal Health, Inc.
    • 6. Cook Group
    • 7. Edwards Lifesciences Corporation
    • 8. ENDOLOGIX, INC.
    • 9. InSitu Technologies Inc.
    • 10. JOTEC GmbH
    • 11. LeMaitre Vascular, Inc.
    • 12. Medtronic Plc
    • 13. MicroPort Scientific Corporation
    • 14. Terumo Aortic
    • 15. W. L. Gore & Associates, Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦